Downward price pressures and volatility experienced by Emergent BioSolutions (EBS) stock have historically been driven by post-pandemic declines in demand for contract manufacturing, asset impairment charges, high debt leverage ratios, and intense commercial competition in its over-the-counter NARCAN product line. Additionally, past regulatory scrutiny regarding manufacturing facilities and ongoing legal investigations have weighed on investor sentiment.